- Home
- LILAK vs TSHA Comparison
LILAK vs TSHA Comparison
Compare LILAK & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | TSHA |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LILAK | TSHA |
|---|---|---|
| Price | $7.96 | $4.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $8.20 | ★ $10.56 |
| AVG Volume (30 Days) | 726.0K | ★ 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $1.05 |
| 52 Week High | $9.13 | $6.02 |
Technical Indicators
Market Signals| Indicator | LILAK | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 48.71 |
| Support Level | $7.76 | $4.45 |
| Resistance Level | $8.43 | $4.80 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.91 | 63.64 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.